Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 18, Pages 7324-7333Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm400815m
Keywords
-
Categories
Ask authors/readers for more resources
Pteridinone-based Toll-like receptor 7 (TLR7) agonists were identified as potent and selective alternatives to the previously reported adenine-based agonists, leading to the discovery of GS-9620. Analogues were optimized for the immunomodulatory activity and selectivity versus other TLRs, based on differential induction of key cytokines including interferon a (IFN-alpha) and tumor necrosis factor a (TNF-alpha). In addition, physicochemical properties were adjusted to achieve desirable in vivo pharmacokinetic and pharmacodynamic properties. GS-9620 is currently in clinical evaluation for the treatment of chronic hepatitis B (HBV) infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available